Medical Devices Series C Investors & VC Firms
439 firms in this list, with a median first check of $1M. 92 of them lead rounds. Generated from verified public data and updated continuously.
JSD Capital, LLC
New YorkSeed–Late Stage$10M
8 people
Southern Cross Venture Partners
NarrabeenSeed–Late Stage$1.3M – $6.6M
5 people
Oost NL
ApeldoornSeed–Late Stage$108K – $5.4M
2 people
Partners Investment Co. Ltd.
SeoulSeries A–Late Stage
10 people
Vertex Ventures HC
SingaporeSeed–Growth$500K – $10M
4 people
Inclusion Japan
Pre-Seed–Growth
Oxford Investment Consultants LLP
OxfordSeed–Late Stage
9 people
Split Rock Partners
Eden PrairieSeed–Late Stage$2M – $40M
4 people
AddVentures by SCG
BangkokSeed–Late Stage$1.5M – $66M
6 people
Novalis LifeSciences
PortsmouthSeed–Late Stage
9 people
Whiz Partners Inc.
TokyoSeed–Late Stage$500K – $5M
6 people
Target Partners
MunichSeed–Late Stage$1.1M – $3.2M
7 people
Mammoth Research
Fort WayneSeries A–Growth
9 people
TRICAPITAL
Scottish BordersSeed–Growth$315K – $2.5M
3 people
Tauros Capital
ViennaSeries A–Growth$2.2M
4 people
InVivium Capital
ChicagoSeed–Late Stage
6 people
Vision Creator
SeoulPre-Seed–Late Stage
EDB Investments
SingaporeSeed–Late Stage$12M – $400M
11 people
Healthcare Venture Partners, Llc
CharlestonSeries B–Late Stage
8 people
JANNGO Capital
AbidjanSeed–Growth
6 people
SBCVC
TortolaSeed–Late Stage
6 people
PBM Capital
CharlottesvilleSeed–Late Stage
6 people
Percipient Capital
LondonSeed–Late Stage$1.3M – $6.3M
3 people
Waterman Ventures
UtrechtSeed–Late Stage
3 people
Related lists
Series C Investors & VC Firms (2842)Medical Devices Investors & VC Firms (1451)Series C Investors & VC Firms in North America (1414)Series C Investors & VC Firms in United States (1223)Medical Devices Seed Investors & VC Firms (1203)Medical Devices Series A Investors & VC Firms (1188)Series C Investors & VC Firms in Asia-Pacific (994)Series C Investors & VC Firms in Europe (960)Medical Devices Investors & VC Firms in North America (945)Series C Investors & VC Firms in Global (936)
Data sourced from public filings and firms' own websites — see our methodology.



































































